Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression

Oliver, R. T. D.; Tobias, Jeffrey; Gallagher, Chris

doi:10.1016/0959-8049(95)00589-7

Cited by 5 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, in this 2-6-week pilot study, breast cancer cell proliferation, as judged by Ki-67 staining, was unaffected by TZD over the period between tissue acquisition by diagnostic biopsy and the surgical procedure with intent to cure. One possibility for this lack of a suppressive effect is that the rosiglitazone was unable to overcome a temporary stimulation of tumour proliferation by locally secreted growth and angiogenic factors (144), including leptin (145), which are produced as part of the healing process after biopsy of the tumour mass (146).…”

Section: Commentarymentioning

confidence: 99%

Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer

2007

View full text Add to dashboard Cite

Upper body obesity and the related metabolic disorder type 2 diabetes have been identified as risk factors for breast cancer, and associated with late-stage disease and a poor prognosis. Components of the metabolic syndrome, including visceral adiposity, insulin resistance, hyperglycemia and hyperinsulinemia, with or without clinically manifest diabetes mellitus, low serum high-density lipoprotein cholesterol and hypertension have all been related to increased breast cancer risk. The biochemical mechanisms include extraglandular oestrogen production, reduced sex hormone-binding globulin with consequent elevation of the bioactive plasma free oestradiol and increased insulin biosynthesis, all of which exert mitogenic effects on both untransformed and neoplastic breast epithelial cells. Obesity, type 2 diabetes and the metabolic syndrome also have in common an increased production of leptin and a decreased production of adiponectin by adipose tissue, with consequent elevations and reductions, respectively, in the circulating levels of these two adipokines. These changes in plasma leptin and adiponectin, acting through endocrine and paracrine mechanisms, have been associated in several studies with an increase in breast cancer risk and, perhaps, to more aggressive tumours; studies in vitro showed that leptin stimulates, and adiponectin inhibits, tumour cell proliferation and the microvessel angiogenesis which is essential for breast cancer development and progression.

show abstract

Section: Commentarymentioning

confidence: 99%

Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer

2007

View full text Add to dashboard Cite

show abstract

“…However, one theory suggests that cell biological changes associated with endocrine therapy may reduce the metastatic potential of cells released by surgery, an advantage for preoperative endocrine therapy. 34 Conversely, there are concerns that preoperative endocrine therapy may select resistant clones within the primary tumor that would not arise if the tumor had been immediately removed. The results of NSABP B-18 suggest that systemic treatment with the primary intact does not increase the number of chemotherapyresistant clones that are later associated with relapse, but this issue remains a theoretical concern for preoperative endocrine therapy.…”

Section: Preoperative Vs Postoperative Endocrine Therapymentioning

confidence: 99%

Preoperative Endocrine Therapy for Older Women with Breast Cancer: Renewed Interest in an Old Idea

Ellis

2000

Cancer Control

View full text Add to dashboard Cite

Preoperative endocrine therapy is a logical approach for older patients with ER+ disease as a well-tolerated means to increase the rate of breast-conserving surgery. Several clinical trials comparing tamoxifen with selective aromatase inhibitors in the preoperative setting have been conducted, and the results are expected soon. These studies will determine if a large multicenter national trial of preoperative endocrine therapy should be conducted.

show abstract

Letters to the editor: Comments on Prebiopsy neoadjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression, oliver et al., EurJ cancer, 32A, No. 3, pp. 396–397, 1996

Mokbel¹

1996

European Journal of Cancer

View full text Add to dashboard Cite

Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression

Cited by 5 publications

References 16 publications

Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer

Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer

Preoperative Endocrine Therapy for Older Women with Breast Cancer: Renewed Interest in an Old Idea

Letters to the editor: Comments on Prebiopsy neoadjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression, oliver et al., EurJ cancer, 32A, No. 3, pp. 396–397, 1996

Contact Info

Product

Resources

About